Ageing Research Reviews
February 1, 2024
Jitendra Kumar Sinha, Anchal Trisal, Shampa Ghosh et al.
29 citations
Psychedelics such as DMT, LSD, and psilocybin, which act as potent 5-hydroxytryptamine agonists, enhance neural plasticity by activating serotoninergic and glutamatergic systems and modulate signaling pathways in Alzheimer's disease, including brain-derived neurotrophic factor signaling and subsequent activation of mammalian target of rapamycin and autophagy regulators. These compounds show potential for mitigating effects of Alzheimer's disease-related dementia, which lacks a definitive cure. Controlled, dose-dependent administration represents a novel therapeutic intervention, though further studies are needed to establish long-term safety, efficacy, and optimal protocols.
Ibrain
January 1, 2023
Bhuvi Sachdeva, Punya Sachdeva, Shampa Ghosh et al.
27 citations
Ketamine, an anesthetic with known psychedelic and psychotropic effects and associated neurotoxicity, is reviewed as a potential therapeutic for major depressive disorder (MDD) and posttraumatic stress disorder (PTSD). MDD affects 300 million people worldwide and involves symptoms such as anhedonia, fatigue, and suicidal ideation; PTSD similarly includes anhedonia and hypervigilance after trauma. The article discusses ketamine's mechanisms of action, findings from clinical trials, and possible side effects, suggesting it may offer an effective treatment option for these debilitating conditions, though its toxicity remains a concern.
Alzheimer s & Dementia
December 1, 2024
Jitendra Kumar Sinha, Shampa Ghosh, Krishna Kumar Singh et al.
1 citation
Psychedelics such as DMT, LSD, and psilocybin, traditionally linked to recreational and spiritual use, are being investigated for therapeutic benefits in Alzheimer's disease-related dementia. These compounds act as serotonin agonists and enhance neural plasticity through serotonin and glutamate systems. They may modulate Alzheimer's-related signaling pathways, including the BDNF pathway, mTOR activation, and autophagy regulators. Controlled administration, depending on dosage, offers a potential novel intervention for dementia. The review highlights promising pathways but emphasizes the need for further studies to establish long-term safety, efficacy, and optimal treatment protocols.